Immutep Ltd has released a press release.
Primary Endpoint Met in STS Trial - presented at ESMO 2025
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- Improved ORR in First Line NSCLC - presented at ESMO 2025
- Immutep Announces Successful Completion of FDA Project Optimus Requirements
- Successful Completion of FDA Project Optimus Requirements
- Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer
- TACTI-004 (KEYNOTE-F91) Phase 3 update in First Line NSCLC
Later from Immutep
- Immutep Quarterly Activities Report Q1 FY26
- Immutep Receives A$4.6 million French R&D Tax Incentive
- Immutep Receives A$4.6 million R&D Tax Incentive from French Government
- EFTISARC-NEO Phase II results presented at CTOS 2025
- Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep